Medicare Enrolled
Dr. Binusha Moitheennazima, MD
Pulmonary Disease · Nacogdoches, TX
Practice pattern: Clinical Cardiology
— Primarily office-based clinical cardiology
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Moitheennazima from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Moitheennazima?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Moitheennazima
Dr. Binusha Moitheennazima is a pulmonary disease specialist in Nacogdoches, TX, with 17 years of NPI registration. Based on federal Medicare data, Dr. Moitheennazima performed 13,478 Medicare services across 3,572 unique beneficiaries.
Between the years covered by Open Payments, Dr. Moitheennazima received a total of $9,216 from 39 pharmaceutical and/or device companies across 464 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in pulmonary disease. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Moitheennazima is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 17 years in practice
▲ Top 0% volume in TX
$9,216 industry payments
Medicare Practice Summary
Medicare Utilization ↗13,478
Medicare services
Top 0% in TX for pulmonary disease
3,572
Unique beneficiaries
$42
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~793 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
2,946 | $94 | $439 |
| Allergy skin test A diagnostic test performed to identify specific allergies by applying or introducing allergenic extracts to the body. The procedure measures the patient's immune response to various potential allergens. |
2,168 | $3 | $13 |
| Allergy immunotherapy preparation A professional service involving the preparation and administration of one or more antigens. |
2,055 | $11 | $53 |
| Spirometry test before and after medication A test that measures the amount of air you can exhale and the speed of your breathing before and after taking a medication. |
1,072 | $27 | $134 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
930 | $0 | $10 |
| Ceftriaxone antibiotic injection This code represents the administration of ceftriaxone sodium, an antibiotic medication. The charge is calculated for every 250 mg of the drug administered. |
912 | $0 | $5 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
509 | $10 | $49 |
| Lung volume test using sensors A test that measures the amount of air in the lungs using sensors. |
330 | $39 | $187 |
| Pulmonary gas exchange test A test to examine how well the lungs exchange gases. |
329 | $41 | $201 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
319 | $63 | $242 |
| Nursing facility visit, moderate complexity A follow-up visit by a healthcare provider at a nursing facility for an established patient. The visit involves moderate medical decision making and takes at least 30 minutes. |
314 | $80 | $336 |
| Critical care, first 30-74 min Emergency medical care for a critically ill or injured patient lasting between 30 and 74 minutes. This service involves direct patient care and medical decision making to stabilize the patient. |
263 | $168 | $949 |
| Influenza virus detection test A laboratory test that uses an immunoassay technique to detect the presence of the influenza virus through direct visual observation. |
246 | $16 | $52 |
| Flu vaccine administration This procedure involves the administration of the influenza virus vaccine. It covers the process of delivering the vaccine to the patient. |
177 | $30 | $39 |
| SARS-CoV-2 immunoassay test A laboratory test using immunoassay techniques to detect the presence of severe acute respiratory syndrome coronavirus. |
167 | $34 | $125 |
| Quadrivalent influenza vaccine, cell culture-derived A flu shot that protects against four strains of the influenza virus. It is produced using cell culture technology rather than traditional egg-based methods. |
143 | $31 | $175 |
| Sleep study with heart rate and breathing monitoring A sleep study that monitors heart rate, breathing, airflow, and physical effort during sleep. |
97 | $70 | $315 |
| Injection, methylprednisolone acetate, 40 mg | 92 | $5 | $41 |
| New patient office visit (45-59 min) An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter. |
73 | $129 | $571 |
| Sleep study with continuous airway pressure, age 6+ A sleep study conducted in a sleep lab that monitors breathing and other body functions while administering continuous airway pressure. This test is performed on patients aged 6 years or older. |
62 | $476 | $2,187 |
| Initial nursing facility care, high complexity An initial visit by a healthcare provider to a patient in a nursing facility involving a high level of medical decision making, lasting at least 45 minutes. |
51 | $135 | $558 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
50 | $138 | $671 |
| Quadrivalent influenza vaccine, cell-culture derived A flu shot containing four strains of influenza virus, produced using cell culture technology rather than eggs. This formulation is free from preservatives and antibiotics. |
38 | $33 | $84 |
| Sleep study in sleep lab (age 6+) An overnight test conducted in a sleep laboratory to monitor sleep patterns and bodily functions in patients aged 6 years or older. |
32 | $466 | $2,088 |
| Sleep study with heart rate and breathing monitoring A sleep study that monitors heart rate, breathing patterns, and sleep duration. This test records physiological data while you sleep to assess your sleep quality and breathing function. |
26 | $116 | $551 |
| Office visit, established patient (20-29 min) An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition. |
24 | $68 | $310 |
| COVID-19 immunoassay detection test A laboratory test that uses an immunoassay method to detect the presence of severe acute respiratory syndrome coronavirus 2 (COVID-19) through direct visual observation. |
22 | $41 | $125 |
| Allergy injection therapy, multiple injections A professional service involving the administration of multiple allergen injections. |
20 | $9 | $39 |
| Transitional care management, high complexity Coordination of care for a patient transitioning from a short-term hospital stay or other facility to home or another care setting. This service addresses a high-complexity medical problem. |
11 | $216 | $958 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
Industry Payment Transparency
Open Payments through 2024 ↗$9,216
Total received (2018-2024)
Avg $1,317/year across 7 years
Top 22% in TX for pulmonary disease
39
Companies
464
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$9,151 (99.3%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$65 (0.7%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$1,813
2023
$1,912
2022
$1,098
2021
$1,048
2020
$808
2019
$1,359
2018
$1,178
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
AstraZeneca Pharmaceuticals LP
$2,274
GlaxoSmithKline, LLC.
$1,843
Boehringer Ingelheim Pharmaceuticals, Inc.
$936
Mylan Specialty L.P.
$660
GENZYME CORPORATION
$558
Genentech USA, Inc.
$324
Sunovion Pharmaceuticals Inc.
$309
Regeneron Healthcare Solutions, Inc.
$218
Paratek Pharmaceuticals, Inc.
$214
JAZZ PHARMACEUTICALS INC.
$164
Actelion Pharmaceuticals US, Inc.
$152
Philips Electronics North America Corporation
$143
Jazz Pharmaceuticals Inc.
$140
Amgen Inc.
$139
PFIZER INC.
$127
Takeda Pharmaceuticals U.S.A., Inc.
$120
Harmony Biosciences LLC
$99
ANI Pharmaceuticals, Inc.
$73
Baxter Healthcare
$68
SANOFI-AVENTIS U.S. LLC
$68
Merck Sharp & Dohme LLC
$63
Philips North America LLC
$63
Pulmonx Corporation
$61
Electromed, Inc.
$43
Merck Sharp & Dohme Corporation
$41
Insmed, Inc.
$40
Advanced Respiratory, Inc
$36
Mallinckrodt LLC
$31
Vapotherm Inc
$30
Vifor Pharma, Inc.
$28
Janssen Pharmaceuticals, Inc
$27
Teva Pharmaceuticals USA, Inc.
$23
kaleo, Inc.
$19
Resmed Corp
$16
Bayer HealthCare Pharmaceuticals Inc.
$15
Gilead Sciences, Inc.
$14
ADVANCED RESPIRATORY, INC
$14
Grifols USA, LLC
$14
United Therapeutics Corporation
$11
Top 3 companies account for 54.8% of total payments
Associated products mentioned in payments ›
(8874) inCourage · (AK6) Vest Therapy · ACTHAR · AIRSUPRA · ANORO · ANORO ELLIPTA · AREXVY · ASMANEX · AUVI-Q · Adempas · Arikayce · Astral · BELSOMRA · BEVESPI AEROSPHERE · BREO · BREZTRI · CHANTIX · CHARTIS CATHETER · CINQAIR · DUPIXENT · Dymista · ELIQUIS · Esbriet · FARXIGA · FASENRA · GLASSIA · Hillrom - Vest System Model 105 Home Care · LONHALA MAGNAIR · NUCALA · NUZYRA · OFEV · OPSUMIT · ORENITRAM · PAXLOVID · PREVNAR 20 · PURIFIED CORTROPHIN GEL · Perforomist · Prolastin-C · SMARTVEST · STIOLTO RESPIMAT · SUNOSI · SYMBICORT · TAGRISSO · TEZSPIRE · TRELEGY ELLIPTA · TUDORZA PRESSAIR · The Vest System Model 105 Home Care · Trilogy 100 · Utibron · Veltassa · WINREVAIR · Wakix · Wellcentive Undiv · XARELTO · XYREM · XYWAV · Xolair · Xyrem · YUPELRI · Yupelri · inCourage
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (99%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Equivalent to $68 per 100 Medicare services performed
Geographic Context
Pulmonary diseases within 10 mi
3
Per 100K population
4.6
County median income
$51,528
Nearest hospital
NACOGDOCHES MEMORIAL HOSPITAL
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Moitheennazima is a clinical cardiology specialist, with above-average Medicare volume (top 0% in TX), with low-engagement industry engagement, with 17 years of NPI registration.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Moitheennazima experienced with office visit, established patient (30-39 min)?
Based on Medicare claims data, Dr. Moitheennazima performed 2,946 office visit, established patient (30-39 min) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Moitheennazima receive payments from pharmaceutical companies?
Yes. Dr. Moitheennazima received a total of $9,216 from 39 companies across 464 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Moitheennazima's costs compare to other pulmonary diseases in Nacogdoches?
Dr. Moitheennazima's average Medicare payment per service is $42. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Moitheennazima) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Specialty guide
Understanding Pulmonary Disease
Common procedures, typical costs, and what industry payments mean in pulmonary disease.
Same specialty & city
Pulmonary Diseases in Nacogdoches
Browse pulmonary diseases in Nacogdoches ranked by procedure volume and transparency data.
Highest volume
Top Pulmonary Diseases in TX
Pulmonary diseases ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Pulmonary Diseases in TX
Which TX pulmonary diseases receive the most from drug and device companies.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
By company
GlaxoSmithKline, LLC. Payments to Doctors
See all physicians who received payments from GlaxoSmithKline, LLC.
By company
Boehringer Ingelheim Pharmaceuticals, Inc. Payments to Doctors
See all physicians who received payments from Boehringer Ingelheim Pharmaceuticals, Inc.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology